Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants

Healthy Participant Clinical Trial

Official title:
COVID-19: A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF PF-07321332/RITONAVIR IN HEALTHY PARTICIPANTS

Status Completed

Clinical Trial Summary

The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of PF-07321332/ritonavir in healthy participants.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Healthy Participant

Clinical Trial Details

NCT number	NCT04962022
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 1
Start date	July 20, 2021
Completion date	September 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05311865` - Transmission of Covid-19 During Clubbing Events in Closed Places	N/A
Recruiting	`NCT05520216` - Effect of Rib Cage and Spine Mobility on Maximum Breath-Hold Time
Active, not recruiting	`NCT04807465` - Different Modes of Universal Adhesive in Smokers and Non-Smokers	N/A
Completed	`NCT06087055` - Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants	Phase 1
Completed	`NCT04962230` - Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir	Phase 1
Completed	`NCT05450549` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants	Phase 1
Active, not recruiting	`NCT04814836` - Laser Etching Effect on Application Mode of Universal Adhesive	N/A